Literature DB >> 25960721

Genotype/Phenotype correlations in patients with hereditary breast cancer.

Maike Wittersheim1, Reinhard Büttner1, Birgid Markiefka1.   

Abstract

Of all breast cancer cases, 5-10% can be attributed to germline mutations, and the high-susceptibility genes BRCA1 and BRCA2 account for about 25-28% of these cases. For the remainder, several genes of moderate and low penetrance have been discovered. Histopathologic characteristics have been studied in small cohorts, but for most of the known non-BRCA1/2-associated hereditary breast cancers, the histologic and immunohistochemical phenotypes are not yet identified. Particularly BRCA1 tumors are associated with a distinct morphology and immunohistochemical characteristics that differ from sporadic breast cancer of age-matched controls. The recognition of features characteristic of these mutations can be helpful to identify patients likely to carry a germline mutation and to assess which gene should be screened for first, in families with a high occurrence of breast and ovarian cancer.

Entities:  

Keywords:  BRCA mutation; Genotype/phenotype correlations; Hereditary breast cancer; Intrinsic subtypes

Year:  2015        PMID: 25960721      PMCID: PMC4395815          DOI: 10.1159/000380900

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  51 in total

Review 1.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

2.  CHEK2-positive breast cancers in young Polish women.

Authors:  Cezary Cybulski; Bohdan Górski; Tomasz Huzarski; Tomasz Byrski; Jacek Gronwald; Tadeusz Debniak; Dominika Wokolorczyk; Anna Jakubowska; Elzbieta Kowalska; Oleg Oszurek; Steven A Narod; Jan Lubinski
Journal:  Clin Cancer Res       Date:  2006-08-15       Impact factor: 12.531

Review 3.  Histological, molecular and functional subtypes of breast cancers.

Authors:  Gautam K Malhotra; Xiangshan Zhao; Hamid Band; Vimla Band
Journal:  Cancer Biol Ther       Date:  2010-11-15       Impact factor: 4.742

Review 4.  Models of genetic susceptibility to breast cancer.

Authors:  A C Antoniou; D F Easton
Journal:  Oncogene       Date:  2006-09-25       Impact factor: 9.867

Review 5.  BRCA1 and its toolbox for the maintenance of genome integrity.

Authors:  Michael S Y Huen; Shirley M H Sy; Junjie Chen
Journal:  Nat Rev Mol Cell Biol       Date:  2009-12-23       Impact factor: 94.444

6.  Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.

Authors:  Alfons Meindl; Heide Hellebrand; Constanze Wiek; Verena Erven; Barbara Wappenschmidt; Dieter Niederacher; Marcel Freund; Peter Lichtner; Linda Hartmann; Heiner Schaal; Juliane Ramser; Ellen Honisch; Christian Kubisch; Hans E Wichmann; Karin Kast; Helmut Deissler; Christoph Engel; Bertram Müller-Myhsok; Kornelia Neveling; Marion Kiechle; Christopher G Mathew; Detlev Schindler; Rita K Schmutzler; Helmut Hanenberg
Journal:  Nat Genet       Date:  2010-04-18       Impact factor: 38.330

7.  Cancer Incidence in BRCA1 mutation carriers.

Authors:  Deborah Thompson; Douglas F Easton
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

8.  p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours.

Authors:  T Crook; L A Brooks; S Crossland; P Osin; K T Barker; J Waller; E Philp; P D Smith; I Yulug; J Peto; G Parker; M J Allday; M R Crompton; B A Gusterson
Journal:  Oncogene       Date:  1998-10-01       Impact factor: 9.867

Review 9.  The complex genetic landscape of familial breast cancer.

Authors:  Lorenzo Melchor; Javier Benítez
Journal:  Hum Genet       Date:  2013-04-05       Impact factor: 4.132

10.  Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q.

Authors:  M R Stratton; D Ford; S Neuhasen; S Seal; R Wooster; L S Friedman; M C King; V Egilsson; P Devilee; R McManus
Journal:  Nat Genet       Date:  1994-05       Impact factor: 38.330

View more
  7 in total

1.  New avenues in secondary and tertiary prevention of breast cancer.

Authors:  Rita K Schmutzler
Journal:  Breast Care (Basel)       Date:  2015-02       Impact factor: 2.860

2.  Regulation of therapeutic resistance in cancers by receptor tyrosine kinases.

Authors:  Mei-Kuang Chen; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2016-03-15       Impact factor: 6.166

Review 3.  Incorporating Genomic and Genetic Testing into the Treatment of Metastatic Luminal Breast Cancer.

Authors:  Sabine Grill; Evelyn Klein
Journal:  Breast Care (Basel)       Date:  2021-01-20       Impact factor: 2.860

4.  Investigation of The Relationship of TNFRSF11A Gene Polymorphisms with Breast Cancer Development and Metastasis Risk in Patients with BRCA1 Or BRCA2 Pathogenic Variants Living in The Trakya Region of Turkey.

Authors:  K Özdemir; H Gürkan; S Demir; E Atli; Y Özen; A Sezer; N Tunçbilek; I Çicin
Journal:  Balkan J Med Genet       Date:  2021-03-23       Impact factor: 0.519

5.  Double heterozygous pathogenic variants prevalence in a cohort of patients with hereditary breast cancer.

Authors:  Thais Baccili Cury Megid; Mateus C Barros-Filho; Janina Pontes Pisani; Maria Isabel Achatz
Journal:  Front Oncol       Date:  2022-08-08       Impact factor: 5.738

Review 6.  Clinical spectrum and pleiotropic nature of CDH1 germline mutations.

Authors:  Joana Figueiredo; Soraia Melo; Patrícia Carneiro; Ana Margarida Moreira; Maria Sofia Fernandes; Ana Sofia Ribeiro; Parry Guilford; Joana Paredes; Raquel Seruca
Journal:  J Med Genet       Date:  2019-01-19       Impact factor: 6.318

7.  Screening of germline mutations in young Rwandan patients with breast cancers.

Authors:  Jeanne P Uyisenga; Karin Segers; Aimé Z Lumaka; Pacifique Mugenzi; Corinne Fasquelle; Bouchra Boujemila; Claire Josse; Leon Mutesa; Vincent Bours
Journal:  Mol Genet Genomic Med       Date:  2020-09-22       Impact factor: 2.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.